-
Capivasertib (CAS: 1143532-39-1)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Capivasertib breast cancer AstraZeneca Mar.10.2030 -
Crisaborole (CAS: 906673-24-3)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Crisaborole Atopic Dermatitis And Eczema Pfizer Jun.29,2029 -
Crisaborole
API’s Name Indication Innovator Patent Expiry Date(The U.S) Crisaborole Atopic Dermatitis and Eczema Pfizer Jun. 11, 2026 -
Canagliflozin
API’s Name Indication Specification US DMF EU DMF CEP Canagliflozin Type 2 diabetes In-House √ -
Chlorothiazide
API’s Name Indication Specification US DMF EU DMF CEP Chlorothiazide Diuretics USP/EP